Clemence Pouzin

Statistics

Publications

Citations

H-Index

Active since

2022

Affiliations

Sanofi (France)(Current)

Université Claude Bernard Lyon 1

Clemence Pouzin is an author at Sanofi (France) specializing in pharmacology, targeted therapy pharmacology, and pharmacokinetics of anticancer drugs.

ORCID

Publications per year

2022–2022

Publications

Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate

Clemence Pouzin, Leonid Gibiansky, Nathalie Fagniez et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2022 · 14 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFβ inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors.

Debbie Robbrecht, Bernard Doger, Jean‐Jacques Grob et al. · Journal of Clinical Oncology · 2022 · 14 citations

Medicine, Oncology, Pharmacology +17

Covariate analysis of tusamitamab ravtansine, a DM4 anti‐CEACAM5 antibody‐drug conjugate, based on first‐in‐human study

Clemence Pouzin, Michel Tod, Mustapha Chadjaa et al. · CPT Pharmacometrics & Systems Pharmacology · 2022 · 11 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

1–3 of 3